- Cancer treatment company Immutep (IMM) has seen improving results from its cancer trials, INSIGHT-004 and TACTI-002
- For the INSIGHT-004 trial, the company is combining its lead product, efti, with avelumab on 12 patients, who all have different solid tumours
- Currently, 41.7 per cent (five of the 12) of the patients have shown a partial response to the combination therapy – an increase from the last result of 33 per cent
- For the TACTI-002 head and neck cancer trial, Immutep has seen the improving overall response rate maintained at 38.9 per cent
- Immutep has reported 67 per cent of the patients are still alive at nine months
- Immutep is currently up almost 20 per cent and trading for 25.8 cents
